Big Pharma Outlook 2026

Datamonitor Healthcare’s Pharmavitae Analytics team casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Developing Better Quality Controls in Advanced Therapy Medicinal Product (ATMP)

Advanced therapy medicinal products (ATMPs) comprise a category of innovative and complex biological products and hold one of the keys to personalised treatment. It holds promises as treatments for untreatable and high burden diseases.
Watch Now

Understanding the Evolution of Intranasal Vaccines

Intranasal vaccination is an interesting and increasingly attractive alternative to improving the delivery of therapeutic vaccines. It comes with the promise of better efficacy by stimulating local mucosal response, needle-free delivery and could be self-administrable.
Watch Now

The top 5 cybersecurity threats to pharma for 2022

It's no secret that pharma companies are struggling to protect themselves from cyberattacks amid the pandemic. Data breaches are costing the sector around US$5m a year, while one in 10 pharma companies are at risk of a ransomware attack, exacerbated by a perfect storm of shifting to remote working, increased growth, antiquated OT systems and a lack of cybersecurity skills.
Watch Now

Long-Acting Injectables: Successful Microsphere Development and Scale-Up

Ashland and Oakwood Laboratories will showcase application of Viatel™ bioresorbable polymers and customized chemistry in long-acting injectable (LAI) microsphere formulations.
Watch Now

Spotlight

resources